Recent

% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. Message Board

  • breezerwave breezerwave Apr 10, 2013 5:25 AM Flag

    Anticipated Clinical Milestones for 2013

    Anticipated Clinical Milestones for 2013

    ACH-3102: Phase 2 second-generation NS5A inhibitor

    Expand the Phase 2 clinical trial evaluating 12 weeks of therapy consisting of ACH-3102 and ribavirin, for the treatment of genotype 1b treatment-naive HCV during the second quarter of 2013;

    Report SVR4 results following 12 weeks of therapy consisting of ACH-3102 and ribavirin for the treatment of genotype 1b, IL28B CC genotype, HCV in the second quarter of 2013; and

    Provide RVR results from the Phase 2 trial of ACH-3102 and ribavirin for genotype 1b treatment-naive HCV during the third quarter of 2013.

    Combination of sovaprevir and ACH-3102 for the treatment of genotype 1 HCV

    Initiate dosing patients in a Phase 2 trial evaluating 12 weeks of sovaprevir and ACH-3102, with ribavirin, for the treatment of genotype 1 HCV during the second quarter of 2013; and

    Report interim Phase 2 results from this first sovaprevir and ACH-3102 combination, including RVR, during the third quarter of 2013.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACHN
8.54-0.06(-0.70%)Aug 26 4:00 PMEDT